- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01325792
Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement (COBRA)
November 18, 2015 updated by: W.L.Gore & Associates
Prospective, Multicenter, Observational Study Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biosynthetic Material for Midline Fascial Closure Reinforcement
Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will evaluate the performance of the biosynthetic mesh when used to reinforce the midline fascial closure in single-staged open complex ventral incisional hernia repair.
It is designed to test the null hypothesis that the two year recurrence rate associated with the device is greater than or equal to 50% vs the alternative hypothesis that the two year recurrence rate is less than 50%.
Study Type
Observational
Enrollment (Actual)
104
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
The Netherlands
-
Nijmegen, The Netherlands, Netherlands
- Canisius-Wilhelmina Ziekenhuis
-
-
-
-
California
-
San Diego, California, United States, 92103
- UCSD Department of Surgery
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York City, New York, United States, 10021
- Mount Sinai Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Medical Center, Case Western Reserve University, Case Western Reserve University
-
-
South Carolina
-
Greenville, South Carolina, United States, 29607
- Greenville Hospital System
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
general and teaching hospitals
Description
Inclusion Criteria:
- Subjects will be informed about the study, and will have read; understood and signed the informed consent and authorization to use their PHI, as applicable
- Subjects willing and able to submit to postoperative follow-up evaluations including quality of life assessments up to 24 months after surgery
- Subjects of either gender that are at least the age of 18 years
- Subjects will have a Body-Mass Index (BMI) of < 40
- Subjects will be undergoing single-staged open complex ventral incisional hernia repair with the retrorectus or intraperitoneal placement technique of the GORE® BIO-A® Tissue Reinforcement
- Subjects in which intraoperatively their surgical field/wound is characterized either a Type 2 or Type 3 in Table 1 in Section 12.0
- Subjects with a hernia defect > 9 cm2 large when measured intraoperatively
- Subjects in which the required mobility for midline fascial closure without excessive tension to reapproximate the rectus abdominis muscle intraoperatively can be achieved
- Subjects in which one unit of GORE® BIO-A® Tissue Reinforcement will adequately reinforce the midline fascial closure with at least 4 cm of overlap laterally
Exclusion Criteria:
- Subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study
- Subjects with a BMI > 40
- Subjects with evidence of pre-existing systemic infections
- Subjects with cirrhosis or are currently being treated with dialysis
- Subjects with a wound-healing disorder
- Subjects with autoimmune disorder requiring > 10mg of a corticosteroid per day
- Subjects who are immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy
- Subjects with a hernia defect < 9 cm2 large when measured intraoperatively
- Subjects with a hernia defect requiring more than one unit of GORE® BIO-A® Tissue Reinforcement
- Subjects in which intraoperatively there is an inability to achieve retrorectus or intraperitoneal placement of the device
- Subjects in which a midline fascial closure without excessive tension cannot be achieved
- Subjects in which intraoperatively their surgical field/wound is characterized either a Type 1 or Type 4 in the Table 1 in Section 12
- Subjects in need of concomitant surgical procedures other than indicated in the protocol as acceptable
- Subject in which their complex ventral incisional hernia repair requires more than one operation to reduce hernia and close fascia, including serial excision procedures - requiring subsequent surgery to complete their hernia repair
- Subjects with a hernia repair requiring an emergent procedure, such as strangulated bowel
- Subjects in which intraoperatively untreated cancer was found
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GORE® BIO-A® Tissue Reinforcement
Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
|
Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hernia Recurrence Rate
Time Frame: at about 24 months
|
Investigator confirmed hernia recurrence by physical examination
|
at about 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early and Long-term Complication Rates
Time Frame: after surgery (day 1) to 24 months
|
Surgical site abdominal wound event rate
|
after surgery (day 1) to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Rosen, MD, University Hospitals Cleveland Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
March 28, 2011
First Submitted That Met QC Criteria
March 29, 2011
First Posted (Estimate)
March 30, 2011
Study Record Updates
Last Update Posted (Estimate)
December 24, 2015
Last Update Submitted That Met QC Criteria
November 18, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS155
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventral Incisional Hernia
-
W.L.Gore & AssociatesRecruitingHernia, Ventral | Hernia Incisional | Hernia Incisional VentralUnited States, Spain, Italy, United Kingdom
-
Universitaire Ziekenhuizen KU LeuvenBelgian Section for Abdominal Wall Surgery, section of the Royal Belgian...Not yet recruitingVentral Incisional Hernia
-
University of PennsylvaniaCompleted
-
Medtronic - MITGCompletedVentral Incisional HerniaFrance
-
Cook Group IncorporatedWithdrawnIncisional Hernias | Ventral Hernias
-
Hospital Central "Dr. Ignacio Morones Prieto"UnknownHernia, Ventral | Ventral Incisional Hernia
-
Varazdin General HospitalCompletedIncisional Ventral Hernia | Recurrent Ventral HerniaCroatia
-
Algemeen Ziekenhuis Maria MiddelaresNot yet recruitingVentral Incisional Hernia
-
Algemeen Ziekenhuis Maria MiddelaresRecruitingVentral Hernia | Umbilical Hernia | Ventral Incisional HerniaBelgium
-
Hospices Civils de LyonRecruiting
Clinical Trials on GORE® BIO-A® Tissue Reinforcement
-
Hospital Universitari Vall d'Hebron Research InstituteUnknown
-
W.L.Gore & AssociatesTerminated
-
W.L.Gore & AssociatesTerminatedRectal Cancer | Ulcerative Colitis | Familial Adenomatous Polyposis | DiverticulitisUnited States
-
University of Firenze and Siena, Napoli, ItalyCompletedOral Soft Tissue ConditionsItaly
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownLoop Ileostomy ClosureSpain
-
W.L.Gore & AssociatesCompletedAortic Diseases | Aortic Aneurysm, Thoracic | Penetrating Ulcer | Descending Thoracic Aortic Dissection | Aorta Thoracic; Traumatic RuptureFrance
-
W.L.Gore & AssociatesRecruitingEnd-Stage Renal Disease | AAA - Abdominal Aortic Aneurysm | PAD - Peripheral Arterial DiseaseSpain, Italy, France
-
W.L.Gore & AssociatesCompletedIatrogenic Vessel Injury
-
W.L.Gore & AssociatesCompleted
-
W.L.Gore & AssociatesCompletedPeripheral Arterial DiseaseJapan